Home » BioMarin to Buy Lead for $97 Million
BioMarin to Buy Lead for $97 Million
Enzyme drugmaker BioMarin Pharmaceutical said it is buying LEAD Therapeutics, a company testing a drug treatment for rare cancers, in a deal worth up to $97 million.
Forbes
Forbes
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May